AstraZeneca eyes merger with Gilead Sciences
AstraZeneca, the pharmaceutical group, has approached U.S. rival Gilead Sciences regarding a potential merger, reported Bloomberg citing people familiar with the matter.
Share this:
AstraZeneca, the pharmaceutical group, has approached U.S. rival Gilead Sciences regarding a potential merger, reported Bloomberg citing people familiar with the matter.
The merger of the two groups would create a giant with a market capitalization of $230 billion.
The merger of the two groups would create a giant with a market capitalization of $230 billion.
An AstraZeneca spokesperson said the group did not comment on rumors or assumptions. Gilead did not wish to comment.
Gilead is particularly active in the treatment of HIV with its drug Biktarvy, which had sales of $1.69 billion in the first quarter.
AstraZeneca also has Tagrisso, a treatment for lung cancer, which generated $982 million in sales in the first three months of the year.
From a chartist's point of view, AstraZeneca escaped from a short term bullish channel and entered into a consolidation move. The daily Relative strength Index (RSI, 14) fell below 50% and is capped by a declining trend line. Bollinger bands are widening.
As long as 8811p is resistance, a decline towards 8046p and 7685p is likely. Alternatively, a push above 8811p would reinstate a bullish bias with 9600p as target.
Source: GAIN Capital, TradingView
AstraZeneca, the pharmaceutical group, has approached U.S. rival Gilead Sciences regarding a potential merger, reported Bloomberg citing people familiar with the matter.
The merger of the two groups would create a giant with a market capitalization of $230 billion.
The merger of the two groups would create a giant with a market capitalization of $230 billion.
An AstraZeneca spokesperson said the group did not comment on rumors or assumptions. Gilead did not wish to comment.
Gilead is particularly active in the treatment of HIV with its drug Biktarvy, which had sales of $1.69 billion in the first quarter.
AstraZeneca also has Tagrisso, a treatment for lung cancer, which generated $982 million in sales in the first three months of the year.
From a chartist's point of view, AstraZeneca escaped from a short term bullish channel and entered into a consolidation move. The daily Relative strength Index (RSI, 14) fell below 50% and is capped by a declining trend line. Bollinger bands are widening.
As long as 8811p is resistance, a decline towards 8046p and 7685p is likely. Alternatively, a push above 8811p would reinstate a bullish bias with 9600p as target.
Source: GAIN Capital, TradingView
Related tags:
Latest market news
The complete CFD trading experience
Award-winning platforms, competitive spreads, low commissions and dedicated support.
We live and breathe the markets and are dedicated to helping traders realise their ambitions as we continue to set the industry bar.
Economic calendar
Web Trader platform
Our sophisticated web-based platform is packed with features.
Related articles
S&P 500, Nasdaq, Dow Forecast: Wall Street Split Widens Into Month-End 9 26 2026
Nasdaq strength contrasts with mounting Dow pressure as rising Treasury yields raise the stakes for stocks heading into the monthly close.
EUR/USD Q4 2026 Outlook: Euro at a Crossroads as Fed, ECB Tighten 9 25 2026
EUR/USD enters Q4 at a pivotal inflection point as competing Fed-ECB policy paths and persistent inflation risks collide with major technical support.
USD/JPY Q4 2026 Outlook: Hawkish Fed Pricing Clashes With Intervention Risk
The year-end tug-of-war is clear: hawkish Fed pricing supports USD/JPY, while intervention risk limits the upside.
StoneX Europe Ltd may make third party material available on this website which may contain information included but not limited to the conditions of financial markets. The material is for information purposes only and does not contain, and should not be construed as containing, investment advice and/or investment recommendation and/or an investment research and/or an offer of or solicitation for any transactions in financial instruments; any decision to enter into a specific transaction shall be made by the client following an assessment by him/her of their situation.
StoneX Europe Ltd makes no representation or warranty and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplied. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. We are not under any obligation to update any such material. Any opinion made may be personal to the author and may not reflect the opinion of StoneX Europe Ltd.